Long-Term Results of Targeted Low-Grade Glioma Treatment with 213Bi-DOTA-[Thi8,Met(O2)11]-Substance P

Cancer Biother Radiopharm. 2019 Aug;34(6):413-416. doi: 10.1089/cbr.2018.2719. Epub 2019 Mar 7.

Abstract

The aim was to evaluate long-term effectiveness, functional outcome, and side effects of targeted α radiotherapy as an alternative treatment for low-grade gliomas (LGGs) in eloquent brain areas. Five patients with gliomas World Health Organization (WHO) II-IV were treated with tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-213Bi substance P. In this study, the LGG patients' (WHO II) clinical and radiological long-term outcome was examined. Ten years after treatment with DOTA-213Bi substance P, both LGG patients are still alive without evidence for tumor recurrence and without new functional deficits. Targeted α radiotherapy of LGG might have the potential of long-term tumor control, due to the short tissue range of α particles especially for eloquently located LGG.

Keywords: Bi; DOTA; glioma; low-grade glioma; substance P; α radiotherapy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Astrocytoma / metabolism
  • Astrocytoma / pathology
  • Astrocytoma / radiotherapy*
  • Brain Neoplasms / metabolism
  • Brain Neoplasms / pathology
  • Brain Neoplasms / radiotherapy*
  • Female
  • Humans
  • Neoplasm Recurrence, Local / prevention & control*
  • Organometallic Compounds / therapeutic use*
  • Prognosis
  • Substance P / analogs & derivatives*
  • Substance P / therapeutic use

Substances

  • Organometallic Compounds
  • substance P, 213Bi-DOTA(thienylalanyl(8)-methionyl(O2)(11))-
  • Substance P